Programming Grants to Accompany NEH on the Road Exhibitions
Deadline : 1-7-2018
Funding Opportunity : PA-15-035
CFDA : 93.273|93.279|93.399|000000
Agency : Department of Health and Human Services
Contact : NIH OER Webmaster
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Eligibility : State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Native American Tribal Governments (Federally recognized)
Public Housing Authorities/Indian Housing Authorities
Native American Tribal Organizations (other than Federally recognized tribal governments)
Nonprofits Having a 501 (c) (3) Status with the IRS (other than institutions of higher education)
Nonprofits that do not have a 501 (c) (3) status with the IRS (other than institutions of higher education)
Private institutions of higher education
For-profit organizations other than small business
Small businesses
Others
Details :
This Funding Opportunity Announcement (FOA) is part of a trans-NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to inform the generation and refinement of novel targets for substance abuse treatment and prevention interventions, modules or adjuncts to existing treatments and prevention interventions that seek to target and modulate behavioral or neurobehavioral processes (e.g., impulsivity, risk-taking propensity, sensation and novelty seeking, distress tolerance, delay discounting, self-regulation, stress reactivity) in adolescents. Additionally, this FOA will encourage studies to include theoretical links that explore the relationship(s) between neural circuitry and treatment and prevention effects, and in particular, how behavioral targets might be affected by treatment and prevention interventions, and how that might be used to improve targeted treatment and prevention development, that translate to reduced morbidity and mortality.
